Future research directions in the use of biomarkers

Environmental Health Perspectives

Volumn 104, Issue SUPPL. 3, 1996, Pages 459-464

  Hemminki, Kari ^a   Kumar, Rajiv ^a   Bykov, Vladimir J ^a   Louhelainen, Jari ^a   Vodicka, Pavel ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b INSTITUTE OF MATHEMATICS   (Czech Republic)

Author keywords

DNA adducts; Genetic epidemiology; Mutation screening; Mutational epidemiology; UV induced mutations; UV photoproducts

Indexed keywords

BIOLOGICAL MARKER; POLYDEOXYRIBONUCLEOTIDE SYNTHASE;

ACCURACY; BIOLOGICAL MONITORING; CANCER; CANCER RISK; CARCINOGENESIS; CONFERENCE PAPER; DNA ADDUCT; GENE MUTATION; GENETIC EPIDEMIOLOGY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MEASUREMENT; OCCUPATIONAL EXPOSURE; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0029990682     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.96104s3459     Document Type: Conference Paper

References (35)

1. Szyfter K, Hemminki K, Szyfter W, Szmeja Z, Banaszewski J, Yang K. Aromatic DNA adducts in larynx biopsies and leukocytes. Carcinogenesis 15:2195-2199 (1994).
2. Mustonen R, Hemminki K. 7-Methylguanine levels in DNA of smokers' and non-smokers' total white blood cells, granulocytes and lymphocytes. Carcinogenesis 13:1951-1955 (1992).
3. 32P-postlabeling analysis of 7-methylguanine in human bronchial and lymphocyte DNA. Carcinogenesis 14:151-154 (1993).
4. 32P-postlabeling of bulky human DNA adducts enriched by different methods including immunoaffinity chromatography. Chem Biol Interact (in press).
5. 32P-HPLC. Carcinogenesis (in press).
6. 32P-postlabelling assay. Carcinogenesis 12:2463-2469 (1993).
7. 32P-postlabelling method for the detection of alkylguanine adducts formed by the reaction of different 1,2-alkyl epoxides with DNA. Carcinogenesis 16: 483-489 (1995).
8. IARC. Monographs on the Evaluation of the Carcinogenic Risks to Humans. Vol 45: Occupational Exposures in Petroleum Refining; Crude Oil and Major Petroleum Products. Lyon: International Agency for Research on Cancer, 1989.
9. Risk Assessment of Urban Air: Emmissions, Exposure, Risk Identification, and Risk Quantitation. Environ Health Perspect 102(Suppl 4):3-210 (1994).
10. IARC. Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 60: Some Industrial Chemicals. Lyon: International Agency for Research on Cancer, 1994.
11. Möller L, Schuetzle D, Autrup H. Future research needs associated with the assessment of potential human health risks from exposure to toxic ambient air pollutants. Environ Health Perpect 102(Suppl 4):193-210 (1994).
12. IARC. Butadiene and Styrene, Assesment of Health Hazards. IARC Sci Publ 127. Lyon:International Agency for Research on Cancer, 1993.
13. Eide I, Hagemann R, Zahlsen K, Törnqvist M, Kumar R, Vodicka P, Hemminki K. Uptake, distribution and formation of hemoglobin and DNA adducts after inhalation of C2-C8 1-alkenes (olefins) in the rat. Carcinogenesis 16:1603-1609 (1995).
14. 32P-postlabeling assay for cisplatin-DNA adducts. Carcinogenesis 15:2829-2834 (1994).
15. 32P-postlabelling. Carcinogenesis 16:113-118 (1995).
16. IARC. Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 55: Solar and Ultraviolet Radiation. Lyon: International Agency for Research on Cancer, 1992.
17. Warmuth I, Harth Y, Matsui MS, Wang N, DeLeo VA. Ultraviolet radiation induces phosphorylation of the epidermal growth factor receptor. Cancer Res 54:374-376 (1994).
18. Szymkowski DE, Lawrence CW, Wood RD. Repair by human cell extracts of single (6-4) and cyclobutane thymine-thymine photoproducts in DNA. Proc Natl Acad Sci USA 90:9823-9827 (1993).
19. Nakazawa H, English D, Randell PL, Nakazawa K, Martel N, Armstrong BK, Yamasaki H. UV and skin cancer: specific p53 gene mutation in normal skin as a biologically relevant exposure measurement. Proc Natl Acad Sci USA 91:360-364 (1994).
20. Ponder BAJ, ed. Genetics of Malignant Disease. Brit Med Bull 50:517-752 (1994).
21. Cotton RGH. Current methods of mutation detection. Mutat Res 285:125-144 (1993).
22. Grompe M. The rapid detection of unknown mutations in nucleic acids. Nat Genet 5:111-117 (1993).
23. Mashal RD, Koontz J, Sklar J. Detection of mutations by cleavage of DNA heteroduplexes with bacteriophage resolvases. Nat Genet 9:177-183 (1995).
24. Hogervorst FBL, Cornelis RS, Bout M, Vanvliet M, Oosterwijk JC, Olmer R, Bakker B, Klijn JGM, Vasen HFA, Meijersheijboer H, Menko FH, Cornelisse CJ, Dendunnen JT, Devilee P, Vanommen GJB. Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet 10:208-212 (1995).
25. Kuypers AWHM, Willems PMW, van der Schans MJ, Linssen PCM, Wessels H,MC, de Brujin CHMM, Everaerts FM, Mensink EJBM. Detection of mutations in DNA using capillary electrophoresis in a polymer network. J Chromatogr 621:149-156 (1993).
26. Khrapko K, Hanekamp JS, Thilly WG, Belenkii A, Foret F, Krager BL. Constant denaturant capillary electrophoresis (CDCE): a high resolution approach to mutation analysis. Nucleic Acids Res 22:364-369 (1994).
27. Burvall K, Ridanpää M, Husgafvel-Pursiainen K, Önfelt A. Separation of transforming N-ras mutations in codons 12,13, and 61 by denaturing gradient gel electrophoresis: investigation based on a set of phagemid constructs. Mutat Res 285:287-294 (1993).
28. Kumar R, Hanekamp JS, Louhelainen J, Burvall K, Önfelt A, Hemminki K, Thilly WG. Separation of transforming amino acid-substituting mutations in codons 12, 13 and 61 of the N-ras gene by constant denaturant capillary electrophoresis (CDCE). Carcinogenesis 16:2667-2673 (1995).
29. Brandt-Rauf PW, DeVivo I, Marion M-J, Hemminki K. The molecular epidemiology of growth signal transduction proteins. J Occup Environ Med 37:77-83 (1995).
30. Partanen T, Hemminki K, Brandt-Rauf P, Jin C-G, Koskinen H. Serum levels of growth factor receptors, EGFR and Neu in asbestosis patients: a follow-up study. Int J Oncol 4:1025-1028 (1994).
31. Partanen T, Hemminki K, Koskinen H, Luo J-C, Carney WP, Brandt-Rauf, PW. The detection of increased amounts of the extracellular domain of the epidermal growth factor receptor in serum during carcinogenesis in asbestosis patients. J Occup Med 36:1324-1328 (1994).
32. McKenzie SJ. Diagnostic utility of oncogenes and their products in human cancer. Biochim Biophys Acta 1072:193-214 (1991).
33. DeVita VT, Hellman S, Rosenberg SA. Cancer, Principles & Practice of Oncology. 4th ed. Philadelphia:J.B. Lippincott, 1993.
34. Adami H-O, Baron J. Screening for prostate cancer: are we ready? Cancer Epidemiol Biomarkers Prev 3:193-195 (1994).
35. Harris CC. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 262:1980-1981 (1993).